MABXIENCE S A has a total of 37 patent applications. Its first patent ever was published in 2014. It filed its patents most often in Taiwan, Uruguay and Argentina. Its main competitors in its focus markets pharmaceuticals, biotechnology and chemical engineering are HEIDELBERG IMMUNOTHERAPEUTICS GMBH, BIOCLIN THERAPEUTICS INC and RADIMMUNE THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Taiwan | 4 | |
#2 | Uruguay | 4 | |
#3 | Argentina | 3 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | Singapore | 3 | |
#6 | United States | 3 | |
#7 | WIPO (World Intellectual Property Organization) | 3 | |
#8 | Australia | 2 | |
#9 | China | 2 | |
#10 | Ecuador | 2 | |
#11 | Hong Kong | 2 | |
#12 | Republic of Korea | 2 | |
#13 | Mexico | 2 | |
#14 | Brazil | 1 | |
#15 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Chemical engineering |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Separation |
# | Name | Total Patents |
---|---|---|
#1 | Thorne Barbara | 12 |
#2 | Raha Tamal | 11 |
#3 | Waugh Stephen | 11 |
#4 | Van Schravendijk Marie Rose | 11 |
#5 | Banado Carlos | 8 |
#6 | Bañado Carlos | 7 |
#7 | Bes Cedric | 6 |
#8 | Mcgarvey Orla | 5 |
#9 | Bes Cédric | 5 |
#10 | Cédric Bes | 4 |
Publication | Filing date | Title |
---|---|---|
US2018016333A1 | Pharmaceutical formulations for anti-tnf-alpha antibodies | |
CN105873601A | Alternative formulations for TNFR: Fc fusion polypeptides | |
TW201444863A | A method for increasing pyro-glutamic acid formation of a protein |